Lumiracoxib
Recommended Musculo-skeletalRestricted
Symptomatic treatment of osteoarthritis.
2
Submissions
1 resub
2005–05
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Jul 2007 Recommended Osteoarthritis no PSD
Access path
- Nov 2005Recommended · restricted
vs celecoxib
- Nov 2005Recommended · restricted
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design.
In the submission to this meeting the sponsor sought listing on a cost-minimisation basis with the equi-effective doses being lumiracoxib 200mg daily = celecoxib 200 daily. PSD · 2005
Decision context
PopulationAdults with symptomatic osteoarthritis (knee or hip).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended · restricted | celecoxib | — | RCT · OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null |
| Nov 2005 | Recommended · restricted | celecoxib | — | RCT |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricted subsidy to osteoarthritis only; TGA label also includes acute/post-operative pain and dysmenorrhoea.